Medivir Announces New Cancer Project, Leukotide, derived from its in-house Nucleotide Platform
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces a new discovery project for a cancer indication. The Leukotide project is intended to deliver a new drug for the treatment of acute myeloid leukemia (AML) and other hematological malignancies, and is based on the company’s expertise in nucleoside and nucleotide science. It represents the second cancer project to emerge from its in-house discovery efforts in oncology. AML arises from cells in the bone marrow that are supposed to develop into normal white blood cells but become cancerous instead. These cancerous cells